Wednesday, September 21, 2016 9:36:12 AM
MSTX - .11 Down .475 so far.
Mast Therapeutics Drops 78% in Post-Market; Phase 3 Drug to Treat Sickle Cell Disease Fails to Meet Endpoint
Mast Therapeutics Drops 78% in Post-Market; Phase 3 Drug to Treat Sickle Cell Disease Fails to Meet Endpoint
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
